UnknownNot Applicable

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

240 participantsStarted 2024-02-01

Plain-language summary

* The prevalence of erthropoietin stimulating agents hyporesponsiveness in hemodialysis patients in Assiut university hospital * Assessment of cardiovascular diseases risk in patients with erythropoiesis stimulating agents hyporesponsiveness in hemodialysis patients in Assiut university hospital

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age more than 18 * End stage renal disease patients undergoing regular hemodialysis in Assiut University Hospital - Hemodialysis unit for duration at least 3 months Exclusion Criteria: * acute infectious disease within one month * active liver disease or cancer * recent blood transfusion or surgical intervention * active bleeding or hemorrhage

What they're measuring

Assessment of the prevalence of Erythropoiesis stimulating agents hyporesponsiveness in dialysis patients in Assiut university hospital

Timeframe: One year

Trial details

NCT IDNCT06053866

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-02-01

Contact for this trial

Feby Rasmy Khalifa

+201015508087 fybyrsmy@gmail.com

View on ClinicalTrials.gov More Erythropoietin Resistant Anemia (EPO Resistant Anemia) trials